Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/43067
Full metadata record
DC FieldValueLanguage
dc.contributor.authorVERBEECK, Johan-
dc.contributor.authorDe Backer, Mickael-
dc.contributor.authorBUYSE, Marc-
dc.date.accessioned2024-06-07T08:05:31Z-
dc.date.available2024-06-07T08:05:31Z-
dc.date.issued2024-
dc.date.submitted2024-06-05T07:45:50Z-
dc.identifier.citationNEW ENGLAND JOURNAL OF MEDICINE, 390 (14) , p. 1345 -1347-
dc.identifier.urihttp://hdl.handle.net/1942/43067-
dc.description.abstractTo the Editor: In a phase 3 trial of acoramidis for transthyretin amyloid cardiomyopathy, Gillmore et al. (Jan. 11 issue)(1) used the Finkelstein-Schoenfeld test to assess the hierarchical composite primary outcome. They expressed the treatment effect as a win ratio, thereby following the initial presentation of the analysis of a prioritized outcome.(2) However, the generalized pairwise comparison method, to which the Finkelstein-Schoenfeld test and the win ratio belong, has evolved substantially since this first application.(3) To aid the interpretation of the results, it is now recommended that the proportions of wins and losses for each outcome are reported to understand the . . .-
dc.language.isoen-
dc.publisherMASSACHUSETTS MEDICAL SOC-
dc.rights2024 Massachusetts Medical Society. All rights reserved.-
dc.titleAcoramidis in Transthyretin Amyloid Cardiomyopathy-
dc.typeJournal Contribution-
dc.identifier.epage1347-
dc.identifier.issue14-
dc.identifier.spage1345-
dc.identifier.volume390-
local.format.pages3-
local.bibliographicCitation.jcatA1-
dc.description.notesVerbeeck, J (corresponding author), Hasselt Univ, Hasselt, Belgium.-
dc.description.notesjohan.verbeeck@uhasselt.be-
local.publisher.placeWALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA-
local.type.refereedRefereed-
local.type.specifiedLetter-
dc.identifier.doi10.1056/NEJMc2401669-
dc.identifier.isi001217044600003-
local.provider.typewosris-
local.description.affiliation[Verbeeck, Johan] Hasselt Univ, Hasselt, Belgium.-
local.description.affiliation[De Backer, Mickael] One2Treat, Mont St Guibert, Belgium.-
local.description.affiliation[Buyse, Marc] Int Drug Dev Inst, Ottignies, Belgium.-
local.uhasselt.internationalno-
item.fullcitationVERBEECK, Johan; De Backer, Mickael & BUYSE, Marc (2024) Acoramidis in Transthyretin Amyloid Cardiomyopathy. In: NEW ENGLAND JOURNAL OF MEDICINE, 390 (14) , p. 1345 -1347.-
item.fulltextWith Fulltext-
item.contributorVERBEECK, Johan-
item.contributorDe Backer, Mickael-
item.contributorBUYSE, Marc-
item.accessRightsEmbargoed Access-
item.embargoEndDate2024-10-10-
crisitem.journal.issn0028-4793-
crisitem.journal.eissn1533-4406-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
24-01414_Proof_hi.pdf
  Until 2024-10-10		Peer-reviewed author version116.36 kBAdobe PDFView/Open    Request a copy
Verbeeck_NEJM.pdf
  Restricted Access		Published version316.82 kBAdobe PDFView/Open    Request a copy
Show simple item record

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.